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BACKGROUND AND METHODS: Novel approaches to treat chemo-refractory metastatic breast cancer (MBC) are currently under
investigation. This retrospective series reviews the outcome of 70 MBC patients who have participated in 30 phase I trials at the Royal
Marsden Hospital from 2002 to 2009.
RESULTS: The median treatment lines before phase I trial entry for MBC was 5 (range: 1–12 lines). The overall response rate was
11.4% (95% CI: 4.0–18.9%) and the clinical benefit rate at 4 months was 20% (95% CI: 10.6–29.3). The median time to progression
was 7.0 weeks (95% CI: 6.4–7.5) and median overall survival was 8.7 months (95% CI: 7.6–9.8) from start of first phase I treatment.
No patients discontinued trial because of treatment-related toxicities. Abnormal lactate dehydrogenase, serum albumin o35mg
per 100ml, X5 previous treatment lines, liver metastases and Eastern Cooperative Group performance status X2 at study entry
were significantly associated with poor overall survival in multivariate analysis.
CONCLUSION: This retrospective analysis provides evidence that patients with MBC tolerate phase I clinical trials and a significant
proportion of patients with chemo-refractory disease, particularly those with triple-negative or Her2-positive breast cancer, may
benefit from treatment.
British Journal of Cancer (2010) 103, 607–612. doi:10.1038/sj.bjc.6605812 www.bjcancer.com
Published online 27 July 2010
& 2010 Cancer Research UK
Keywords: metastatic breast cancer; phase I trials; drug resistance
                                                 
In spite of the recent advances in drug development, most women
with metastatic breast cancer (MBC) have a limited median
survival time of approximately 18–24 months, and only around
20% will be alive 5 years after the initial diagnosis of metastatic
disease (Smigal et al, 2006; Chia et al, 2007b). The main aims of
treatment are to reduce disease-related symptoms and improve
quality of life and secondarily to prolong progression-free survival
(PFS) and overall survival (OS) (Smith, 2006). The treatment of
MBC includes chemotherapy, endocrine therapy, radiotherapy,
bisphosphonates, biological therapy or combinations of these,
together with supportive care and, in certain cases, resection of
primary tumour or other surgical procedures. Selection of
treatment is made on an individual basis taking into consideration
patient- and disease-related factors (Guarneri and Conte, 2009).
Although regulatory authority approval for first-line treatment is
based on OS data from randomised clinical trials, approval for
second- and third-line treatment is usually based on time to
progression (TTP) or PFS (Cortazar et al, 2008).
Although MBC is usually sensitive to initial lines of standard
approved drugs, acquired drug resistance and treatment failure is
almost inevitable. The mechanisms of resistance are complex and
can occur at many different levels. These include increased drug
efflux and decreased drug influx, drug inactivation, alterations in
drug target, processing of drug-induced damage, evasion of
apoptosis and activation of alternative cellular survival pathways
(Longley and Johnston, 2005; Gonzalez-Angulo et al, 2007). Novel
approaches to overcome resistance are currently under investiga-
tion with new targeted agents against specific survival pathways
and some patients who remain sufficiently well are offered early
experimental phase I trials.
Appropriate advice at this stage of the disease course for
patients with MBC remains uncertain because of the limitations of
existing literature documenting patient outcome in early phase
clinical trials. A recent retrospective analysis published by the MD
Anderson Cancer Center (Wheler et al, 2010) specifically reviews
the outcome of patients with MBC who have participated in phase I
clinical trials in a single institution. In this study, patients have a
median OS of 6.7 months; baseline characteristics of heavily
pretreated disease, low albumin and poor Eastern Cooperative
Group (ECOG) performance status (PS) are significantly associated
with a shorter survival. Hence, we have performed an analysis in a
UK institution to further characterise this cohort of breast cancer
patients.
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sMATERIALS AND METHODS
The outcome of all patients with MBC who were treated in 30
phase I trials in the Drug Development Unit at the Royal Marsden
Hospital (RMH) between October 2002 and October 2009 was
analysed. For those patients who had participated in more than
one phase I trial, only the first trial entry was considered for
survival analysis. All patients had progressive disease (PD) at study
entry. Baseline characteristics were all collected within 2 weeks
before starting a phase I trial. Patients were observed in weekly
visits for adverse event and concomitant medication recording.
Response to treatment was monitored by MRI or CT scan every
6–8 weeks and reviewed by internal consultant radiologists
according to response evaluation criteria in solid tumours
(Therasse et al, 2000). Patients continued on trial if there was
evidence of response to therapy or stable disease (SD). Dose
adjustments for toxicity were permitted and tumour histology
was reviewed in the RMH pathology laboratory.
The hospital electronic database and clinical notes were used to
collect date of diagnosis of metastatic disease, start and finish dates
of phase I therapy, previous treatment lines, radiological response,
date of disease progression, last follow-up and death. Variables
that were included in the final univariate and multivariate analyses
were: age, gender, sites of disease, treatment lines, tumour patho-
logy, PS and laboratory parameters. The SPSS Program (Version
12.0; SPSS, Chicago, IL, USA) was used for statistical analysis. The
Kaplan–Meier method was applied to estimate TTP and OS.
The Cox regression model was applied for the estimation of the
hazard ratio (HR); and for the multivariate analysis using a forward
selection. Log-rank test (Mantel–Cox) was used to compare survival
distributions. All P-values presented are two sided.
RESULTS
A total of 70 patients with MBC who participated in 30 different
phase I trials at the RMH over 7 years between October 2002 and
October 2009 were analysed. The start date was chosen because of
the expansion in early phase trials using targeted therapeutics that
commenced from this period. Baseline characteristics are shown in
Table 1. The median age at the start of phase I therapy was
51.5 years (range: 34–82 years) and the median number of cycles
on a phase I study was 2 (range: 1–11 cycles). The median time
from diagnosis of metastatic disease to start of phase I treatment
was 24 months (range: 2–102 months); the total median number of
lines of treatment for metastatic disease was 5 (range: 1–12 lines)
comprising 1 line of hormonal therapy (range: 0–4) and 4 of
chemotherapy (range: 0–8 lines). In total, 65 out of 70 patients
(92.9%) had received adjuvant chemotherapy. More than 50% of
patients had received anthracycline, taxane, capecitabine and
vinorelbine chemotherapy-based regimes before phase I trial
entry. In all, 12 out of 70 (17.1%) patients had received previous
biological therapies, excluding trastuzumab, (bevacizumab 4
patients; lapatinib 8 patients). The median number of sites of
metastatic disease before phase I trial entry was 3 (range: 1–5
sites); and the most common sites were: distant lymph nodes
(90%), liver (52.8%), lung (52.8%), skin–chest wall recurrence
(44.2%) and bone (37.1%). In total, 8 out of 70 patients (11.4%)
had an ECOG PS of 2 at study entry.
In all, 26 out of 70 (37.1%) patients had triple-negative breast
cancer (TNBC), 23 out of 70 (32.9%) were oestrogen receptor (ER)-
positive/HER2-negative and 21 out of 70 (30.0%) were HER2-
positive. Table 2 reviews the outcome and main class of targeted
agents used within these trials based on breast cancer subtype.
Overall 8 out of 70 patients (11.4%, 95% CI: 4.0–18.9%) obtained
a partial response (PR), 12 out of 70 patients (17.1%, 95% CI:
8.3–26.0%) had SD and 50 out of 70 patients (71.4%, 95% CI:
60.8–82.0%) had (PD) at first radiological assessment. The overall
clinical benefit rate (PRþSD) at 4 months was 20% (95% CI:
10.6–29.3). When excluding those patients who received cytotoxic
chemotherapy, the response rate for first in human trials was 6.56%
(95% CI: 0.35–12.77%) and the clinical benefit rate at 4 months was
11.48% (95% CI: 3.48–19.47%). Patients with TNBC derived the
greatest benefit, with a response rate of 23.08% (95% CI: 6.8–39.2%)
and were treated more frequently with poly (ADP-ribose) polymerase
(PARP) inhibitors or chemotherapy combinations. There were no
tumour responses among the 23 patients with ER-positive/HER2-
negative disease.
Table 3 shows the characteristics of those patients who achieved
a PR and the specific agents with evidence of anti-tumour activity.
These drugs included tyrosine kinase inhibitors (TKIs) against
vascular endothelial growth factor receptor (VEGFR), epidermal
growth factor receptor (EGFR) pathways and PARP inhibitors
alone or in combination with platinum chemotherapy. Two
patients received a phase I trial as first line for metastatic disease
as this comprised acceptable chemotherapy for the first-line
management of MBC in combination with a targeted agent. No
patients discontinued trial treatment because of toxicity and the
toxic death ratio was 0%. In total, 4 patients out of 70 (5.7%) were
known to have a germline mutation in BRCA2 and 1 (1.4%) was
known to have a BRCA1 mutation. Overall 12 patients were treated
with PARP inhibitor monotherapy. Of these, five patients with
documented germline BRCA mutation had a median TTP of
5 months (range: 3–7months) (Table 4). The remaining seven
patients, all with TNBC, had disease progression at first radiology
assessment at 6 weeks.
The median OS was 8.7 months (95% CI: 7.6–9.8 months) and
the median TTP was 7.0 weeks (95% CI: 6.4–7.5 weeks) for the
whole cohort of MBC patients (Figure 1). The OS univariate
analysis for prognostic factors at phase I trial (Table 5) entry
revealed that cumulative lines of treatment for metastatic disease,
presence of liver metastases, lactate dehydrogenase (LDH) above
the upper limit of normal, poor ECOG PS and low serum albumin
were associated with shorter survival times. All factors remained
significantly associated with a poorer prognosis in the MVA for
OS. In addition, the MVA for TTP revealed that patients treated
with PARP inhibitor-based trials had a significantly longer
Table 1 Baseline characteristics
Baseline characteristics of 70 patients Total
Median age 51.5 years (range: 34–82 years)
Median number of cycles on phase I 2 (range: 1–11 cycles)
Median lines of standard treatment 5 lines (range: 1–12 lines)
Median lines of chemotherapy 4 lines (range: 0–8 lines)
Median sites of metastatic disease 3 sites (1–5 sites)
Receptor status
TNBC 26 (37.1%)
HER2 positive 21 (30.0%)
ER positive/HER2 negative 23 (32.9%)
Previous class of chemotherapy received
Anthracycline 65 (92.9%)
Taxane 62 (88.6%)
Capecitabine 55 (78.6%)
Vinorelbine 38 (54.3%)
Platinum 28 (40%)
Gemcitabine 13 (18.6%)
CMF 4 (5.7%)
Other 4 (5.7%)
ECOG PS at study entry
PS 0 22 (31.4%)
PS 1 40 (57.1%)
PS 2 8 (11.4%)
Abbreviations: ER¼oestrogen receptor; HER2¼epidermal growth factor receptor 2;
PS¼performance status; TNBC¼triple-negative breast cancer.
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stime until disease progression (Cox regression HR: 0.45 (95% CI:
0.23–0.86), P¼0.015). Serum albumin or LDH, liver metastases,
ECOG PS, heavily pretreated disease and chemotherapy-based
phase 1 trials were not significantly associated with TTP in the
MVA (data not shown).
DISCUSSION
The primary aims of phase I clinical trials in oncology are to find a
dose schedule for future development of new anticancer agents and
to describe the toxicity profile of these novel compounds (Roberts
et al, 2004; Horstmann et al, 2005). Patients with advanced breast
cancer who are offered experimental treatment at this stage usually
have disease that is refractory, or has become resistant, to
approved drugs and appropriate treatment recommendations
remain uncertain because of the limited potential for therapeutic
benefit associated with phase I trials. The survival of 8.7 months
observed in this retrospective series is likely to be a reflection of
Table 2 Treatment outcomes for patients based on breast cancer subtypes
Triple-negative
breast cancer
ER-positive/HER2-negative
breast cancer
HER2-positive
breast cancer Total/overall
Median overall survival (95% CI) 8.5 months (4.9–12.2) 8.7 months (3.9- 13.5) 8.7 months (7.3–10.2) 8.7 months (7.6- 9.8)
Median time to progression (95% CI) 8.8 weeks (5.8–11.8) 6.5 weeks (5.7–7.3) 7.4 weeks (6.5–8.3) 7.0 weeks (6.4–7.5)
RECIST response rate 6/26 (23.0%) 0/23 (0%) 2/21(9.5%) 8/70 (11.4%)
CBR (PR+SD) at 4 months 8/26 (30.7%) 2/23 (8.7%) 4/21 (19%) 14/70 (20%)
Type of phase 1 trial
First in human 20 22 19 61
Chemotherapy combination 6 1 2 9
Target of phase 1 trial
DNA repair (PARP) 12 4 1 17
AKT/PI3K/ MTOR pathways 5 3 2 10
Hormone synthesis 0 8 4 12
Growth factor receptor pathways 1 0 3 4
Anti-angiogenesis 2 0 3 5
Cell cycle and apoptosis 3 0 1 4
Chromatin remodelling and antisense 0 5 1 6
Protein turnover (HSP90) 0 2 3 5
Other signalling pathways (Ras, SRC, IGF, c-met) 3 1 3 7
Total 26 23 21 70
Abbreviations: CBR¼clinical benefit rate; CI¼confidence interval; ER¼oestrogen receptor; HER2¼epidermal growth factor receptor 2; IGF¼insulin-like growth factor;
PARP¼poly (ADP-ribose) polymerase; PD¼progressive disease; PR¼partial response; RECIST¼response evaluation criteria in solid tumours; SD¼stable disease; SRC¼
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; TNBC¼triple-negative breast cancer.
Table 3 Characteristic of patients who responded to phase 1 treatment with single targeted agents and chemotherapy combinations
Trial Age Pathology
Lines chem.
MTX
Previous chem.. class
received (including adj.)
Lines horm.
MTX Biological
PARP 45 IDC, Horm–, HER , BRCA2 1 Tax, Anthra 0 No
TKI VEGF 53 IDC, Horm–, HER  2 Tax, Anthra, Lip. doxorubicin 0 No
TKI VEGF 58 IDC, Horm–, HER  5 Tax, Anthra, Gem 0 No
TKI EGF/HER2 66 IDC, Horm (ER)+, HER+ 7 Tax, Anthra, Cape, Plat, Gem 4 Trast/Lap
PARP/Carbo Paclit 48 IDC, Horm–, HER– 0 Tax, Anthra 0 No
PARP/Carbo Paclit 50 IDC, Horm–, HER– 0 Tax, Anthra 0 No
PARP/Carbo Paclit 35 IDC, Horm–, HER– 1 Tax, Anthra 0 No
SRC/Carbo Paclit 59 IDC, Horm+, HER+ 5 Tax, Anthra, Cape 2 Trast
Abbreviations: adj.¼adjuvant; Anthra¼anthracyclines; Cape¼capecitabine; Carbo¼carboplatin; chem.¼chemotherapy; EGF¼epidermal growth factor; ER¼oestrogen
receptor; Gem¼gemcitabine; HER2¼epidermal growth factor receptor 2; horm¼hormonal; IDC¼invasive ductal carcinoma; Lap¼lapatinib; Lip.¼liposomal;
MTX¼metastatic disease; PARP¼Poly (ADP-ribose) polymerase; Paclit¼paclitaxel; Plat¼platinum salts; Tax¼taxanes; Trast¼trastuzumab; TKI¼tyrosine kinase inhibitor;
TNBC¼triple-negative breast cancer; VEGF¼vascular endothelial growth factor.
Table 4 Characteristics’ of patients with germline BRCA mutation
treated with PARP inhibitor monotherapy
Patient 26 28 35 66 67
TTP (months) 7 5537
a
Best response SD SD SD SD PR
ER status Negative Positive Negative Positive Negative
PR status Negative Negative Negative Negative Negative
HER2 status Negative Negative Negative Negative Negative
BRCA status BRCA1 BRCA2 BRCA2 BRCA2 BRCA2
Pathology IDC IDC IDC IDC IDC
Lines chemo MTX 4 2121
Time MTX to
phase I
22 months 16 months 20 months 27 months 12 months
Abbreviations: ER¼oestrogen receptor; HER2¼epidermal growth factor receptor 2;
IDC¼invasive ductal carcinoma; MTX¼metastatic disease; PARP¼Poly (ADP-ribose)
polymerase; PR¼progesterone receptor; TTP¼time to progression.
aOngoing PR at
radiological 7-month assessment. Partial response (PR) and stable disease (SD)
according to response evaluation criteria in solid tumours (RECIST).
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sthe characteristics of breast cancer patients who participate in
phase I trials, for example, heavily pretreated disease and multiple
sites of disease at trial entry. The MVA of prognostic factors at
study entry confirmed that abnormal serum LDH (a potential
surrogate of disease burden), low serum albumin, poor PS, liver
metastases and X5 lines of previous treatment were associated
with worse outcome. This supports previous retrospective and
prospective reports from our institution across all tumour types
(Arkenau et al, 2008a,b, 2009). Patient selection based on
prognostic factors can potentially minimise the burden to those
who are the least likely to benefit from phase I treatment and
therefore should not be considered for trial entry. Phase I trials
frequently exclude patients with PSX2 and potentially other
factors may be used to guide this selection.
Interestingly, the recent report from the MD Anderson Cancer
Centre showed that patients with MBC referred to their Phase I
unit tend to be heavily pretreated and have shorter survival times
compared with a broader range of advanced cancers (Wheler et al,
2009). The shorter median OS of 6.7 months in comparison with
our series probably results from patient heterogeneity and the
intention-to-treat analysis used, which includes poor prognostic
patients with complications from PD before trial entry and
screening failures. Low serum albumin, heavily pretreated disease
and poor PS were also confirmed to be associated with poor
survival outcomes in their MBC cohort. Patient’s characteristics
seem to be comparable between both series, although the
percentage of patients with TNBC was slightly higher in our study
potentially reflecting referral of these patients for PARP inhibitor
and platinum salt-based trials ongoing in our phase I unit.
Although these data from a retrospective analysis of breast cancer
patients treated in phase I trials at a single institution can only be
interpreted in an exploratory manner, some interesting points can
be highlighted. Phase I trials have often in the past recruited a wide
spectrum of patients with different tumour types. In the era of
targeted therapies, however, this approach may need to change, in
a number of ways. It is hoped, for example, that molecular
characterisation of breast cancer will lead to more individualised
treatment according to specific tumour type. In addition, 10% of
patients were referred for a phase 1 trial in our analysis having only
received one or two previous treatment lines for MBC, compared
to 20% in the MD Anderson series. The response rate of 11.4%
observed in our retrospective study combined with a significant
number of patients obtaining clinical benefit, which was highest in
the TNBC subtype, may suggest that referral of patients earlier in the
disease course for phase I trials may be a reasonable option,
particularly for patients with relatively chemo-refractory disease or
subtypes of breast cancer with limited standard options.
Although the retrospective comparison should be interpreted
with caution, the median TTP was significantly longer for patients
treated with PARP inhibitor-based trials relative to the rest of the
cohort. A total of 17 patients were treated with PARP inhibitors in
this retrospective analysis. Five patients with TNBC received a
PARP inhibitor in combination with a platinum salt. A majority of
these patients were not heavily pretreated and thus these figures
may potentially overestimate response in early phase clinical trials.
In addition, 12 patients were treated with monotherapy at doses in
which activity was observed in other tumour types and 5 out of
these 12 patients had BRCA germline mutation and derived
significant clinical benefit as shown in Table 4. Interestingly, the
remaining seven patients (all with TNBC) had PD at first radiology
assessment after PARP inhibitor treatment, suggesting that mono-
therapy alone is insufficient to offer disease control in patients
without documented germline BRCA mutations. Promising activity
has been confirmed with platinum salts in the treatment of TNBC
(Chia et al, 2007a; Sirohi et al, 2008; Silver et al, 2010) and recent
trials have shown PARP inhibition to be highly effective in TNBC
and in patients with germline mutations of BRCA1 or BRCA2
(Fong et al, 2009; O’Shaughnessy et al, 2009).
Vascular proliferation has been shown to be an important
element in tumour growth with numerous studies showing
reduced survival times for patients with high levels of vascular
endothelial growth factor (VEGF) expressed by breast primary
tumours (Gasparini et al, 1997; Linderholm et al, 1998). Further-
more, a recent retrospective analysis showed significantly higher
intra-tumoral levels of VEGF for patients with primary operable
TNBC (Linderholm et al, 2009). In our series, there were four
patients treated with TKI compounds targeted against VEGFR
family members. Two patients with chemo-resistant TNBC had
a radiological PR after a TKI. On the basis of these preliminary
data, and recent phase II neo-adjuvant trial analysis of cisplatin
and bevacizumab in TNBC (Ryan et al, 2009), in which a clinical
CR was observed in 12 patients (26%) and a PR was observed in
24 patients (52%), prospective analysis of TKI against VEGFR
in TNBC are anticipated with interest.
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0.4
0.2
0.0
Median TTP 7.0 weeks (95% Cl: 6.4–7.5)
Progression: 66 patients
Censored: 4 patients
Median OS 8.7 months (95% Cl: 7.6–9.8)
Death: 53 patients
Censored: 17 patients
1.0
0.8
0.6
0.4
0.2
0.0
TTP (weeks)
Kaplan-Meier curve for time to progression
OS (months)
Kaplan-Meier curve for overall survival
06 1 2 24 18
01 2 3 6 24 72 60 48
Figure 1 Time to progression (TTP) and overall survival (OS) Kaplan–
Meier curves for the whole cohort of patients with MBC.
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sMechanisms of resistance to HER2-directed therapy include
impaired binding of trastuzumab to HER2, PIK3CA mutation and
PTEN loss that promote activation of downstream receptor
signalling (Stemke-Hale et al, 2008). One of the two patients with
HER2þ trastuzumab-resistant disease in our analysis who
achieved a PR received an irreversible small molecule inhibitor
of EGFR and HER2. This patient was heavily pretreated with
multiple lines of cytotoxics, hormonal therapy, and two lines of
HER2-directed targeted therapy (trastuzumab and lapatinib). In
addition, 10 patients in this series received novel agents targeting
the PI3K-AKT pathway but unfortunately there were no PRs or
prolonged SD to agents targeting this pathway.
This paper highlights many of the challenges in developing
effective drugs for breast cancer. In particular, for this process to
be as cost- and time-effective as possible, phase I trial designs need
to be able to adapt to rapidly evolving changes in molecular
biology and the technological advances resulting from this (Carden
et al, 2010). These must be facilitated by validated preclinical
tumour models, which are critical to aid understanding of which
agents are likely to benefit in different breast cancer subtypes
(Mirzoeva et al, 2009). In addition, integrative assessment of key
oncogenic drivers at the DNA, mRNA and protein level, together
with analysis of feedback loops in combination with functional
genomics RNA interference approaches to elucidate drug resis-
tance pathways (Juul et al, 2010) may have value in determining
appropriate combinations of targeted agents and the defined
tumour molecular subtypes in which to use them. These will aid
the ability to conduct successful hypothesis-testing clinical trials
for targeted agents in breast cancer in molecularly distinct tumour
types, with better use of predictive, pharmacodynamic and
response biomarkers. Early patient referral in selected tumour
types and chemo-refractory disease may augment the chance of
benefit to experimental therapies. In addition, selection of patients
based on prognostic tools can assist go-no-go decisions on trial
participation for those least likely to benefit.
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